Díaz DO, Cabrera RE, Orlandi GN, Araña RMJ, Díaz HO

Idioma: Español
Referencias bibliográficas: 22
Paginas: 3-10
Archivo PDF: 55.05 Kb.

FRAGMENTO

La pandemia de obesidad y diabetes que existe en la actualidad en los países desarrollados y que cada vez se incrementa más en los países en vías de desarrollo, no tiene, por ahora, posibilidad de detenerse, y sobre la base de definiciones actuales, millones de personas en Estados Unidos tienen prediabetes, y algunos ya están afectados por alteraciones microvasculares. La prediabetes aumenta en 5 a 6 veces el riesgo absoluto de diabetes tipo 2, y puede ser aún mayor en ciertos grupos poblacionales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933-46.

2. The International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-34.

3. Álvarez Seijas E, González Calero TM, Cabrera-Rode E, Conesa González AI, Parlá Sardiñas J, González Polanco EA. Algunos aspectos de actualidad sobre la hemoglobina glucosilada y sus aplicaciones. Rev Cubana Endocrinol. 2009;20(3):141-51.

4. Randie R. Littlea and David B. Sacksb. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes. 2009;16:113-8.

5. Nordin G, Dybkaer R. Recommendation for term and measurement unit for HbA1c. Clin Chem Lab Med. 2007;45:1081-2.

6. Consensus statement on the worldwide standardization of the haemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care. 2007;30:2399- 400.

7. Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobulin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr [serie en internet] 2010 [citado 13 de febrero de 2011]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21195416

8. Mrena S, Savola K, Kulmala P, Akerblom HK, Knip M, the Childhood Diabetes in Finland Study Group. Natural course of preclinical type 1 diabetes in siblings of affected children. Acta Paediatr. 2003;92:1403-10.

9. Mrena S, Virtanen SM, Laippala P, Kulmala P, Hannila MI, Åkerblom HK, and the Childhood Diabetes in Finland Study Group. Models for Predicting Type 1 Diabetes in Siblings of Affected Children. Diabetes Care. 2006;29:662-7.

10. Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol-related diaseases in subjects diagnosed as diabetic and impaired glucose tolerance: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44:465-74.

11. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Sudy. Diabetes Care. 1995;18:1270-3.

12. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988- 1994. Diabetes Care. 1998;21:518-24.

13. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survey. Diabetologia. 2001;44:1094-101.

14. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalence of diabetes and impaired glucose regulation in a Danish population-The Inter99 Study. Diabetes Care. 2003;26:2335-40.

15. YH Dong, WG Gao, HR Nan, for the Qingdao Epidemiology Study Group. The prevalence of diabetes and the risk factor in Chinese population in Qingdao city. 18th International Diabetes Federation Congress, Paris, France, 24-29 August 2003. Diabetes Metab. 2003;29:4S21.

16. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and prediabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32:287-94.

17. Escobelo J, Buitrón LV, Velasco MF, Ramírez JC, Hernández R, Macchia A, et al, and behalf of the CARMELA Study Investigators. High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. Diabet Med. 2009;26:864-71.

18. Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen B, Ramachandran A, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia. 2004;47:1396-402.

19. Staiger H, Machicao F, Kantartzis K, Schafer SA, Kirchhoff K, Guthoff M, et al. Novel meta-analysis type 2 diabetes risk loci do not determine prediabetic phenotypes. PLos ONE [serie en internet]. 2008 [citado 9 de septiembre de 2009];3:e3019. Disponible en: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2500187&blobtype=pdf

20. Mrena S, Savola K, Kulmala P, Reijonen H, Ilonen J, Åkerblom HK, et al, and the Childhood Diabetes in Finland Study Group. Genetic modification of risk assessment based on staging of preclinical type 1 diabetes in siblings of affected. Children. J Clin Endocrinol Metab. 2003;88:2682-9.

21. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.

22. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933-46.